149591-20-8Relevant articles and documents
Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials
McConville, Matthew,Fernández, Jorge,Angulo-Barturen, í?igo,Bahamontes-Rosa, Noemi,Ballell-Pages, Lluis,Casta?eda, Pablo,De Cózar, Cristina,Crespo, Benigno,Guijarro, Laura,Jiménez-Díaz, María Belén,Martínez-Martínez, Maria S.,De Mercado, Jaime,Santos-Villarejo, ángel,Sanz, Laura M.,Frigerio, Micol,Washbourn, Gina,Ward, Stephen A.,Nixon, Gemma L.,Biagini, Giancarlo A.,Berry, Neil G.,Blackman, Michael J.,Calderón, Félix,O'Neill, Paul M.
, p. 6448 - 6455 (2015)
(Graph Presented) Screening of the GSK corporate collection, some 1.9 million compounds, against Plasmodium falciparum (Pf), revealed almost 14000 active hits that are now known as the Tres Cantos Antimalarial Set (TCAMS). Followup work by Calderon et al.
Pharmaceutical use of N-carbamoylazole derivatives
-
, (2008/06/13)
The present invention relates to use of 1-carbamoylazole derivatives as medicaments and pharmaceutical compositions containing 1-carbamoylazole derivatives as the active ingredient, based on their DPPIV inhibiting effects. The present invention provides a
Pharmaceutical use of N-Carbamoylazole derivatives
-
Page 25-26, (2010/11/29)
The present invention relates to use of 1-carbamoylazole derivatives as medicaments and pharmaceutical compositions containing 1-carbamoylazole derivatives as the active ingredient, based on their DPPIV inhibiting effects. The present invention provides a dipeptidyl peptidase IV inhibiting agent comprising a compound represented by the general formula (I):